Short-Term Debt to Equity Ratio: Vistagen (VTGN)
This daily price chart for Vistagen Therapeutics (VTGN) is based on the company's ownership of exclusive patents in the field of neurosteroids, while the short-term debt-to-equity ratio stands at 0.03. Growth is expected to be driven by upcoming final trials of an innovative treatment for social anxiety disorder. Business development relies on partnerships with specialized scientific centers to refine emergency relief medications.
Analytical breakdowns for VistaGen Therapeutics Inc (VTGN)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Vistagen Therapeutics|VTGN - Long-Term Debt to Equity|Short-Term Debt to Capital Vistagen Therapeutics|VTGN - Company Total Debt Obligations|Debt to Book Capitalization Ratio VistaGen Therapeutics, Inc.|VTGN - Long-Term Debt Volume|Company Current Liabilities Vistagen|Quick Ratio vistagen.com
- company profitability and valuation multiples indicators:
Basic company analysis:VTGN Vistagen
This ratio determines the share of short-term borrowings within the equity structure, measuring the ability of the company's assets to cover urgent credit obligations without risking insolvency. By analyzing the ratio of short-term liabilities to equity, investors assess the financial stability of Vistagen Therapeutics (VTGN), which is critical for management when financing the development of innovative nasal sprays for anxiety disorders.
Main competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Ratio CPRX|Short-Term Debt to Equity DNLI|Short-Term Debt to Capital HRMY|Short-Term Debt to Capital Coefficient Biohaven Ltd|Short-Term Debt to Equity Amylyx AMLX|Short-Term Debt to Capital Coefficient Trevi Corp (TRVI)|PRAX: Short-Term Debt to Equity Ratio|anavex.com - Short-Term Loans to Capital Ratio|CBLL: Short-Term Debt to Capital|Prothena Biosciences (PRTA) - Short-Term Debt to Capital|ALEC (Alector Inc.) - Short-Term Debt to Capital|ANNX - Short-Term Indebtedness to Equity|Short-Term Debt to Capital OMER|NGNE - Current Liabilities to Capital|Short-Term Debt to Equity AC Immune SA ACIU|VYGR: Short-Term Debt to Capital Ratio|NMRA: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN (Tevogen Bio Holdings) - Short-Term Debt to Equity Ratio|ACOG: Short-Term Loans to Capital Ratio|CGTX (Cognition Therapeutics, Inc.) - Short-Term Debt to Capital|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital SAVA|ASRT - Current Liabilities to Capital|Short-Term Debt to Equity Coya Therapeutics COYA|Ratio of Short-Term Indebtedness to Capital OVID|Acumen Pharmaceuticals, Inc. - Short-Term Debt to Capital|CRVO - Short-Term Debt to Capital|alteritytherapeutics.com (ATHE) - Short-Term Debt to Equity|Current Liabilities to Equity CLNN (Clene)|PEPG (PepGen Inc) - Short-Term Debt to Capital|Current Liabilities to Capital jupiterneurosciences.com JUNS|Short-Term Debt to Equity Ratio RLMD (Relmada Therapeutics, Inc.)|Short-Term Debt to Capital Annovis Bio Inc (ANVS)|Grace Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio AIFF (Firefly Neuro)|ANEW Medical, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient NeuroSense Therapeutics NRSN|RVPH: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio MetaVia|Short-Term Debt to Equity NeurAxis, Inc|Helius Medical Technologies Inc. (HSDT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio PASG (Passage Bio, Inc.)|Short-Term Debt to Equity NEUP (bionomics.com.au)|Minerva Neurosciences, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio ATHA (Athira Pharma Inc)|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Alzamend Neuro, Inc. (ALZN)|cyclerion.com (CYCN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio PTIX|Short-Term Debt to Equity Pasithea Therapeutics Corp|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Capital ATXI|BCLI - Current Liabilities to Capital|Cara Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital chromocell.com CHRO|ELYM - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ITCI (Intra-Cellular Therapies)|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Current Liabilities to Capital Marinus Pharma (MRNS)|Short-Term Debt to Equity Ratio NKGN|Short-Term Debt to Equity NRBO|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Coefficient Synaptogenix Inc.|Short-Term Debt to Equity Trevena, Inc TRVN|Short-Term Debt to Capital Coefficient Vigil Neuroscience Inc. (VIGL)|WENA: Short-Term Debt to Equity Ratio|cerevel.com - Short-Term Loans to Capital Ratio